Individualized feedback of volatile agent use reduces fresh gas flow rate,but fails to favorably affect agent choice

Background Cost reduction has become an important fiscal aim of many hospit als and anesthetic departments, despite its inherent Limitations. Volatile anesthetic agents are some of the few drugs that are amenable to such treat ment because fresh gas low rare (FGFR) can be independent of patient volati le anesthetic agent requirement. Methods: FGFR and drug use were recorded at the temporal midpoint of 2,031 general anesthetics during a 2-month preintervention period. Staff and resi dents were provided with their preintervention individual mean FGFR, their peer group mean, and educational material regarding volatile agent costs an d low-flow anesthesia. FGFR and drug use were remeasured over a 2-month per iod (postintervention) immediately after this information (N = 2,242) and a gain 5 months later (delayed followup), for a further 2-month period (N = 2 ,056). Results: for all cases, FGFR decreased from 2.4 +/- 1.1 to 1.8 +/- 1.0 l/mi n (26% reduction) after the intervention and increased to 1.9 +/- 1.1 l/min (5% increase of preintervention FGFR) at the time of delayed follow-up. Us e of more expensive volatile agents (desflurane and sevoflurane) increased during the study period (P < 0.01), In a subgroup of 44 staff members with more than five cases in all study periods, 42 members decreased their mean FGFR after intervention. At delayed follow-up, 30 members had increased the ir FGFR above postintervention FGFR but below their initial FGFR, After acc ounting for other predictors of FGFR, the effectiveness of the intervention was significantly reduced at follow-up (28% reduction), but retained a sig nificant effect compared to preintervention FGFR (19% reduction). Conclusions: Although individual feedback and education regarding volatile agent use was effective at reducing FGFR, effectiveness was reduced without continued feedback. Use of more expensive volatile agents was not reduced by education regarding drug cost, and actually increased.